Last updated on July 2019

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Brief description of study

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Clinical Study Identifier: NCT03112174

Find a site near you

Start Over

City of Hope

Duarte, CA United States
  Connect »

Orlando Health Inc.

Orlando, FL United States
  Connect »

Ingalls Memorial Hospital

Harvey, IL United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

Stony Brook University

New York, NY United States
  Connect »

Levine Cancer Institute

Charlotte, NC United States
  Connect »

Tennessee Oncology

Chattanooga, TN United States
  Connect »

Swedish Cancer Institute

Seattle, WA United States
  Connect »

Icon Cancer Care

Auchenflower, Australia
  Connect »

Austin Health

Heidelberg, Australia
  Connect »

AZ Groeninge

Kortrijk, Belgium
  Connect »

FN Olomouc

Olomouc, Czechia
  Connect »

FN Ostrava

Ostrava-Poruba, Czechia
  Connect »

Centre Hospitalier Lyon Sud

Pierre Benite cedex, France
  Connect »

CHU de Tours

Tours Cedex 01, France
  Connect »

The Churchill Hospital

Oxford, United Kingdom
  Connect »

Barts Health NHS Trust

London, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.